ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock Holdings Lifted by Two Sigma Investments LP

Two Sigma Investments LP grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 12.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,243,442 shares of the biopharmaceutical company's stock after purchasing an additional 133,186 shares during the period. Two Sigma Investments LP owned about 0.75% of ACADIA Pharmaceuticals worth $22,817,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Barclays PLC grew its stake in shares of ACADIA Pharmaceuticals by 126.2% in the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock valued at $4,269,000 after buying an additional 154,854 shares in the last quarter. SG Americas Securities LLC lifted its stake in ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after acquiring an additional 1,966,607 shares during the last quarter. KBC Group NV grew its position in ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 2,044 shares in the last quarter. R Squared Ltd bought a new stake in ACADIA Pharmaceuticals in the fourth quarter worth approximately $47,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of ACADIA Pharmaceuticals by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 35,281 shares of the biopharmaceutical company's stock worth $647,000 after purchasing an additional 3,378 shares during the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ACAD has been the topic of a number of recent research reports. Oppenheimer restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Friday, May 16th. Royal Bank of Canada restated an "outperform" rating and set a $26.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday. Robert W. Baird upped their price target on ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Monday. StockNews.com raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Wednesday. Finally, UBS Group reduced their target price on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a report on Monday, April 28th. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $26.83.

Insider Activity at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $22.50, for a total transaction of $90,000.00. Following the completion of the transaction, the insider now owns 20,395 shares in the company, valued at $458,887.50. This trade represents a 16.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark C. Schneyer sold 2,000 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the sale, the executive vice president now directly owns 62,130 shares in the company, valued at approximately $1,553,250. This represents a 3.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,994 shares of company stock valued at $453,131 over the last quarter. 26.50% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Trading Up 0.7%

Shares of ACAD stock opened at $21.85 on Thursday. ACADIA Pharmaceuticals Inc. has a 12 month low of $13.40 and a 12 month high of $25.23. The company has a market capitalization of $3.66 billion, a P/E ratio of 28.01 and a beta of 0.47. The stock has a 50 day moving average of $16.20 and a two-hundred day moving average of $17.22.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.10 by $0.01. The firm had revenue of $244.32 million during the quarter, compared to analysts' expectations of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. ACADIA Pharmaceuticals's quarterly revenue was up 18.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. Sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.